Effect of lipid reduction on the progression of renal disease: A meta-analysis  by Fried, Linda F. et al.
Kidney International, Vol. 59 (2001), pp. 260–269
CLINICAL NEPHROLOGY – EPIDEMIOLOGY – CLINICAL TRIALS
Effect of lipid reduction on the progression of renal disease:
A meta-analysis
LINDA F. FRIED, TREVOR J. ORCHARD, and BERTRAM L. KASISKE, for the LIPIDS AND
RENAL DISEASE PROGRESSION META-ANALYSIS STUDY GROUP
Renal Electrolyte Division, University of Pittsburgh School of Medicine, Renal Section, Medical Service, VA Pittsburgh
Healthcare System, and Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh,
Pennsylvania; and Department of Medicine, Division of Nephrology, Hennepin County Medical Center, Minneapolis,
Minnesota, USA
Conclusions. Lipid reduction may preserve glomerular fil-Effect of lipid reduction on the progression of renal disease:
tration rate and may decrease proteinuria in patients with renalA meta-analysis.
disease.Background. It has been proposed that hyperlipidemia con-
tributes to the progression of renal disease. A large trial has
not been performed; however, a number of small, controlled
trials have been reported. We examined the effects of antili-
Hyperlipidemia is a common complication of nephroticpemic agents on glomerular filtration rate and proteinuria or
syndrome and renal insufficiency. Patients with nephroticalbuminuria in patients with renal disease.
Methods. We used Medline, abstracts from scientific meet- syndrome invariably have elevated total and low-density
ings, and bibliographies from recent reviews and scientific re- lipoprotein (LDL) cholesterol. Often, triglycerides are
ports to locate pertinent studies. Thirteen prospective con- increased as well, and high-density lipoprotein (HDL)trolled trials examining the effects of antilipemic agents on
cholesterol may be low [1]. Patients with progressiverenal function, proteinuria, or albuminuria were included. Stud-
ies were published as full reports or abstracts and were at least renal failure, but without significant proteinuria, often
three months in duration. For five of the studies, individual have abnormalities in circulating lipoproteins as well.
patient data were obtained. Other summary data were indepen- Hypertriglyceridemia, for example, is evident when the
dently extracted from the published reports by two investiga-
glomerular filtration rate (GFR) is less than 30 mL/min.tors and included study quality, subject characteristics, cause
However, elevations of apoC-III and a reduction in theof renal disease, change in serum cholesterol, blood pressure,
glomerular filtration rate, proteinuria, and albuminuria. apoA-1/ApoC-III ratio occur earlier in renal disease [2].
Results. There was a lower rate of decline in glomerular The apoA-1/apoC-III ratio is a marker of the efficiency
filtration rate with treatment compared with controls (treated of removal of triglyceride-rich lipoproteins [2].controls, 0.156 mL/min/month; 95% CI, 0.026 to 0.285 mL/
For almost 100 years, it has been suggested that hyper-min/month, P 5 0.008). The study results were statistically
lipidemia could cause renal injury. More recently, Moor-homogeneous, and in a regression analysis, the effect of treat-
ment on glomerular filtration rate did not correlate with study head et al proposed that lipid abnormalities might con-
quality, the percentage change in cholesterol, the type of lipid- tribute to the progression of renal disease [3]. In a number
lowering agent, or the cause of renal disease. However, longer
of animal models, lipogenic diets worsen, while choles-follow-up correlated with the amount of improvement in glo-
terol-lowering medications ameliorate renal injury [4–8].merular filtration rate from treatment (P 5 0.007). There was
a tendency for a favorable effect of treatment on protein or Epidemiological studies also suggest a role for hyperlip-
albumin excretion [Ln (treatment) 2 Ln (control) 5 20.248, idemia in the progression of diabetic nephropathy [9, 10].
95% CI, 20.562 to 0.064, P 5 0.077]. However, these results Although there have been no large investigations exam-were statistically heterogeneous between studies (P , 0.001).
ining the effects of cholesterol reduction on nephropa-No obvious explanation for this heterogeneity was apparent
thy, several small, controlled trials have recently beenin a regression analysis examining potential reasons for differ-
ences in study results. reported. We performed a meta-analysis of these trials
to assess the effect of antilipemic agents on nephropathy.
Key words: hyperlipidemia, nephropathy, progressive renal disease,
proteinuria, albuminuria, glomerular filtration rate.
METHODS
Received for publication May 3, 2000 Study selectionand in revised form July 10, 2000
Accepted for publication July 13, 2000 We searched Medline to July 1, 1999, to locate trials
examining the effects of lipid-lowering therapy on renalÓ 2001 by the International Society of Nephrology
260
Fried et al: Lipid reduction on renal disease 261
disease progression, using the key words hyperlipidemia, sured in both treatment and control groups as the differ-
cholesterol, diabetes, diabetic nephropathy, progression, ence in GFR before and after treatment and control.
kidney disease, and nephrotic syndrome. The bibliogra- We divided this difference by the duration of follow-up
phies of these and other recent articles were reviewed (in months) to determine the rate of change in GFR (mL/
to locate additional studies. We also searched abstracts min/month). The second end point that we examined was
from major nephrology meetings that occurred in the change in proteinuria or urine albumin excretion. We
past 10 years, including the American Society of Ne- used the natural logarithm of the values for proteinuria
phrology and the International Congress of Nephrology. or urine albumin excretion to calculate this endpoint,
We included studies that were published as full reports that is, Ln (UPAfter) 2 Ln(UPBefore), where UPAfter was
in peer-reviewed journals or as abstracts. We included the urine protein or albumin excretion measured after
only studies that were prospective and were controlled completing the treatment or control period and UPBefore
with a parallel or crossover design control group. Studies was the urine protein or albumin excretion measure be-
that were uncontrolled, or used historical controls, were fore initiating treatment or control. The natural loga-
not included. We excluded studies that treated subjects rithm was used to transform these data, since protein
for less than three months and studies that examined and albumin excretion data are usually not normally
the effects of only diet or dietary supplements on renal distributed [16–18]. In addition, the logarithmic transfor-
function or proteinuria. In particular, we excluded stud- mation enabled us to combine different measures of pro-
ies that examined the effects of fish oil or other dietary tein or albumin excretion as a single endpoint (as the
fatty acid supplements. logarithm of the difference would be without units). The
studies used several different methods for measuring
Data extraction this end point, including (1) timed urine collections to
Authors were asked to provide patient-specific data measure protein, (2) timed urine collections to measure
(without unique identifiers). Despite our best efforts, albumin, (3) protein to creatinine ratios on untimed urine
only the authors from 5 of the 12 studies that were ulti- collections, or (4) albumin to creatinine ratios on un-
mately included in the analysis provided individual pa- timed urine collections. There is a direct relationship
tient data [11–15]. These individual data were used in between protein excretion rates determined on timed
the calculation of endpoints and variances. In addition, and untimed collections [19, 20]. For example, UP 5
the individual patient data were used to calculate the PCR 3 C, where UP is 24-hour urine protein, PCR is
covariance of end-point values before and after interven- protein creatinine ratio, and C is a constant. Therefore,
tion or placebo, and the means of these covariances were
Ln(UPAfter) 2 Ln(UPBefore) 5 Ln(PCRAfter 3 C) 2 (PCRBefore 3 C)used to estimate the covariance (and thereby calculate
variance) for studies where the covariance was not 5 Ln[(PCRAfter 3 C)/(PCRBefore 3 C)]
known (discussed later in this article). Further data on
5 Ln(PCRAfter/PCRBefore)studies presented as abstracts were obtained from data
presented at the scientific meeting. 5 Ln(PCRAfter) 2 Ln(PCRBefore)
Two investigators independently extracted data. Dif-
The same is true for timed and untimed urine albuminferences were resolved by conferencing. We extracted
excretion [21]. In addition, at a given level of proteindata on study quality. To assess possible effects of study
excretion, the proportion of protein that is albumin isquality on results, we defined a study quality index in
relatively constant [21]. Since in most studies subjectswhich two points were assigned if patients were allocated
had approximately the same level of protein excretion,to treatment and control groups randomly. Two points
a similar crude equivalence of the logarithmically trans-were assigned if a parallel group design was used. One
formed albumin and protein excretion differences canpoint was assigned if a crossover design was used. One
be assumed. Several of the studies included in the analy-point was assigned if the inclusion and exclusion criteria
sis had either individual patient data on albumin or pro-were clearly delineated. One point was assigned if sub-
tein excretion [11–15] or published logarithmically trans-jects were masked, and one point was assigned if investi-
formed geometric means with the antilog values of theirgators were masked. We also extracted data on the age of
standard errors [22, 23]. These allowed calculation ofsubjects, their gender, the cause of renal disease (diabe-
the difference in protein or albumin excretion betweentes, glomerulonephritis, or other/unknown), the change
treatment and controls, as well as its variance (discussedin serum cholesterol, and the change in blood pressure
later in this article). However, in the other six studies,in treatment and control groups.
this was estimated as the logarithm of the mean of un-
Renal function and urine protein excretion transformed data [abstracts; Scanferla et al, Am J Hyper-
tens 4:868, 1991; Olbricht et al, International SymposiumThe major endpoint of interest was change in esti-
mated GFR (mL/min). In most studies, this was mea- on Lipids and Renal Disease, 1999, Kashikojima, Japan
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(October 8–11, 1998), p 29; Nishimura et al, Am Soc where tdf is the 97.5th percentile of the t-distribution for
degrees of freedom 5 k 2 1, and k is the number ofNephrol 10:131A, 1999; Buemi et al, J Am Soc Nephrol
studies. This is a conservative choice for the number of10:69A, 1999] [24, 25]. In these cases, the variance of the
degrees of freedom, since the actual number of degreeschange in proteinuria or albuminuria was imputed as the
of freedom lies between k 2 1 and n 2 1, where n ismean variance across studies that allowed us to calculate
the total number of patients included in the combinedthis variance accurately.
trials. Had we selected n for the degrees of freedom, t
Statistical analysis would have approximated 1.96, and the confidence inter-
vals would have been narrower.For the i-th study, the difference in GFR caused by
We looked for homogeneity of treatment effects withtreatment (t) was calculated as:
the test statistic:
DGFRti 5 GFRti2 2 GFRti1
Q 5 o
i
wi(yi 2 yw)2
where GFRti1 was the mean GFR before treatment, and
GFRti2 was the mean GFR after treatment. The variance where Q is approximately a x2 statistic with k 2 1 degrees
of DGFRti caused by treatment in the i-th study was of freedom [26]. Q was used to test whether the variance
estimated as follows: of the treatment effect from the population mean of
treatment effects was significantly different from 0 (theSti2 5 SDti12 1 SDti22 2 2g · SDti1 · SDti2
null hypothesis). To address the possible effects of heter-
where SDti1 is the standard deviation of GFRti1, SDti2 is ogeneity of treatment effects, we also combined the re-
the standard deviation of GFRti2, and g is the covariance sults of trials using a random effects model as described
between GFRti1 and GFRti2. The g was calculated from by DerSimonian and Laird [27].
individual patient data, and a mean of gs was used in Analysis was carried out using a Microsoft Excel Ó
cases in which no individual patient data were available. spreadsheet and the Statistical Package for the Social
In the same manner, we also calculated DGFRc and Sci2 Sciences (SPSS) Ó software package. Results were consid-
for the placebo control group (c). We then calculated the ered significant for two-tail P , 0.05. Values are ex-
difference between treatment and control, yi 5 DGFRti 2 pressed as means and 95% confidence intervals unless
DGFRci and the variance of the difference (yi) was calcu- indicated otherwise.
lated as:
RESULTSSi2 5 1 1nti 1
1
nci
2 · (nti 2 1) · Sti
2 1 (nci 2 1) · Sci2
nti 1 nci 2 2
,
Thirteen studies met the inclusion and exclusion crite-
ria (Table 1). For the remainder of the results, the studieswhere nti and nci were the numbers of patients in the
will be referred to by letter designation in Table 1. Onetreatment and control groups, respectively. We calcu-
study did not have sufficient data to calculate renal func-lated 95% confidence intervals for each study yi as fol-
tion (G), and two did not have data on protein excretionlows:
or albuminuria (A, L). Thus, 12 studies were combined
yi 6 Si · tdf(i) in an analysis of the effects of treatment on change in
GFR. In these 12 studies, 362 of 384 (94%) of patientswhere tdf(i) is the 97.5th percentile of the t-distribution
completed the follow-up. In 11 studies with data on pro-with degrees of freedom 5 nti 1 nci 2 1. The differences
teinuria, 246 of 262 (94%) patients completed follow-between treatment and control for proteinuria (logarith-
up. Reasons that some patients in five of the trials didmically transformed) were calculated in an analogous
not complete the follow-up varied (B–D, H, and J). Inmanner.
the remainder of the studies, there was no mention ofWeighted means and confidence intervals were then
enrolled subjects being dropped or excluded.calculated for the combined differences between treat-
The percentage of patients in each study who werement and control groups using a fixed-effects model. The
male varied from 25 to 80% (mean of study proportionsweighted mean treatment effect was calculated as:
was 61%). The mean age of patients in each study ranged
yw 5 Rwiyi/Rwi from 36 to 65 years (mean of study means was 49 years).
In seven studies, all patients had diabetes. In three stud-where yi is the difference between treatment and control
ies, all had glomerulonephritis. In two trials, 76 to 81%for the ith study, and wi 5 1/Si2 is the inverse of the
had glomerulonephritis, and in one study, the cause ofvariance of yi. The 95% confidence interval of this
renal disease was not indicated (Table 1). Ten trials wereweighted mean treatment effect was calculated as:
randomized and controlled (Table 1). One trial assigned
every other patient to treatment or control (H). Twoyw 6 Ö 1/Rwi 3 tdf
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trials used a randomized, crossover design (G, J). In six L’Abbe´ plot failed to reveal any marked heterogeneity
between the trials (Fig. 3) [28].trials, both the investigators and subjects were masked
In a regression analysis (using the difference in GFR(B–D, I–K). In four trials, neither investigators nor sub-
between treatment and control as the dependent variablejects were masked (A, E, G, H). In one trial, the subjects,
and weighting by least squares with inverse variance),but not the investigators, were masked (F). In two trials,
the only statistically significant correlate with the effectinformation on masking was not available (L, M). Four
of treatment was the duration of follow-up [effect ofof the studies have appeared only in abstract form, while
lipid lowering on change in GFR 5 0.036 3 (follow-upthe remainder were published in peer-reviewed journals.
in months) 2 0.323; P 5 0.007]. There was a trend forIn all but two studies (K, M), data on the change in
a more beneficial effect of treatment in studies of bettertotal cholesterol were available. The difference between
quality (r 5 0.563, P 5 0.057), and there was a similartreatment and control in the percentage change in total
trend for a more beneficial effect in larger studies (r 5cholesterol was 210.1% for gemfibrozil (I). For probu-
0.547, P 5 0.066). There was no relationship betweencol, the difference between treatment and control in the
the effect of treatment and age, gender, cause of renalpercentage change in total cholesterol was 211.2% (L).
disease, type of lipid lowering agent used, percentageAmong the nine studies that reported the effects of an
change in cholesterol, the method for measuring GFR,HMG-CoA reductase inhibitor on the change in total
or the difference in treatment and control in the (loga-cholesterol, the difference between treatment and con-
rithmically transformed) urine protein/albumin excre-trol in the percentage reduction in total cholesterol was
tion change. In a multivariate model, only duration of225.5% (mean of the study means), range 216.2% to
follow-up independently correlated with the effect of235.3%. In six studies that examined the effects of
treatment on the change in GFR. To examine the effectsHMG-CoA reductase inhibitors, we were able to calcu-
of duration of follow-up further, we combined the eightlate that the difference between treatment and control
trials of greater than six months duration (fixed effectsin percentage change in mean arterial blood pressure
model) and found that the effect of treatment was 0.157was 22.8% (range of 28.9 to 2.6%). In Rayner, Byrne,
(0.024 to 0.290, P 5 0.008). In contrast, the effect ofand van Zyl Smit (H), one patient on simvastatin had a
treatment in the four trials with follow-up of six monthsrise in creatinine phosphokinase (CPK) to 761 [13]. In
or less was 20.200 (22.838 to 2.439, P 5 0.810).Zhang et al (G), simvastatin was associated with a statis-
Using the fixed effects method for combining trials,tically significant, but clinically insignificant change in
the mean weighted effect of treatment on change in urineCPK (49 6 23 to 68 6 49) [25]. No other serious adverse
protein or albumin excretion was 20.283 (20.427 toevents were reported.
20.139, P , 0.001). However, the chi-square test for
Four studies measured GFR with plasma clearance of
heterogeneity between the studies was statistically sig-51Cr-EDTA (B, C, F, H). Two measured GFR with renal nificant (P , 0.001), questioning the validity of combin-
clearance of inulin (D, K), five with renal clearance of ing the results for proteinuria. Indeed, the results were
creatinine (E, I, J, L, M), and one with plasma clearance not statistically significant using the random effects
of 99mTc-DPTA (A). Five studies measured urine albumin method for combining trials, where the mean weighted
excretion in timed 24-hour or overnight collections (B, mean was 20.249 (20.562 to 0.064, P 5 0.077; Fig. 4).
C, G, J, M); three studies measured urine protein excre- A funnel plot failed to suggest that there was publication
tion in timed collections (D, E, F). Two measured pro- bias (Fig. 5). In a regression analysis (using the difference
tein:creatinine ratios (H, M), and one measured albu- in logarithmically transformed proteinuria or albumin-
min:creatinine ratio (I). uria between treatment and control as the dependent
The mean weighted effect of lipid-lowering treatment variable and weighting by least squares with inverse vari-
on the change in GFR was 0.156 (0.026 to 0.285) mL/ ance), there were no statistically significant correlations
min/month (P 5 0.008), indicating that treatment with between reductions in proteinuria and the study quality
lipid-reducing agents had a favorable effect on GFR, index, sample size, age, gender, cause of renal disease,
that is, less decline (Fig. 1). A chi-square test for hetero- percentage change in cholesterol, or difference between
geneity between the studies was not statistically signifi- treatment and control in GFR. There was possibly a
cant, supporting the validity of pooling these trial results. trend for an effect of duration of follow-up on the effect
Indeed, the combined treatment effect and confidence of treatment on proteinuria (r 5 20.453, P 5 0.162). To
intervals were the same for the random effects model. examine further the effects of duration of follow-up on
When the trial that was not truly random (it assigned heterogeneity in protein excretion results, we combined
treatment to every other patient) was excluded, [13], the the six trials of greater than six months duration and
resulting effect of treatment remained at 0.156 (0.025 to found that the (random effects model) effect of treat-
0.289) mL/min/month (P 5 0.008). A funnel plot failed ment was 20.450 (20.783 to 20.116, P , 0.001). In
contrast, the effect of treatment in the five trials withto suggest that there was publication bias (Fig. 2). A
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Fig. 1. Difference in change in the glomeru-
lar filtration rate (GFR) for each individual
study (r) and the combined results using a
random effects model (e). Horizontal lines
indicate 95% confidence intervals. The num-
ber in parentheses is the number of patients
who completed each study.
Fig. 2. Funnel plot for the included studies shows the sample size versus
the difference in GFR.
Fig. 3. L’Abbe´ plot of differences in GFR between treatment and
control, with the area of the circle corresponding to the number of
patients included in each study. Circles above the diagonal line indicate
follow-up of six months or less was 20.017 (20.804 to a beneficial effect of lipid-lowering agents on GFR compared with
control.0.570, P 5 0.936).
DISCUSSION publication bias (Fig. 2) or for heterogeneity in the re-
Although studies in animal models have found a favor- sults of the trials (Fig. 3). To our knowledge, this is
able effect of lipid reduction on the progression of renal the first reported meta-analysis examining the effects
disease, the results of trials in humans are less clear. of lipid-lowering therapy on renal function. A previous
Most controlled trials have been too small to make a meta-analysis that examined the effects of lipid-lowering
definitive conclusion. We used meta-analysis to pool the therapy on lipoproteins did not investigate its effects on
results of controlled clinical trials examining the effects renal function or proteinuria in patients with renal dis-
of lipid-lowering therapy on renal function and protein- ease [29].
uria. We found that lipid reduction had a beneficial effect The reduction in GFR from lipid-lowering agents in
on the decline of GFR (Fig. 1). In only one trial (the this study was 0.16 (0.03 to 0.27) mL/min/month or 1.9
largest) was there a statistically significant effect of lipid (0.3 to 3.4) mL/min/year, and this compares favorably
lowering on GFR (abstract; Nishimura et al, Am Soc to the effect of converting enzyme inhibitors on the rate
of change in renal function. Indeed, in a meta-analysisNephrol 10:131A, 1999). There was little evidence for
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Fig. 4. Difference in change in albuminuria
or proteinuria [Ln(treatment) 2 Ln(control)]
for each individual study (r) and the com-
bined result using a random effects model (e).
Horizontal lines indicate 95% confidence in-
tervals. The number in parentheses equals the
sample size.
analysis. The number of trials and the numbers of pa-
tients in the trials were relatively small. Moreover, there
were many differences in the patients that were studied,
the trial designs that were used, and the methods for
measuring GFR and proteinuria. Particularly problem-
atic is the interpretation of changes in proteinuria, given
the heterogeneity in the results of the individual trials.
It is not clear how to handle summary data when there
is heterogeneity, and many believe that pooled results
can be uninterpretable in the presence of heterogeneity
[26, 32, 33]. Meta-analysis implies that a mean value
estimating the effects of treatment can be determined
by combining similar trials, and this is not the case when
the outcome results of those trials are significantly het-
erogeneous [26]. We also performed regression analysis
Fig. 5. Funnel plot for the included studies shows the sample size versus
to identify patient or study characteristics associated withdifference in proteinuria or albuminuria [Ln(treatment) 2 Ln(control)].
the change in GFR or proteinuria and thereby identify
possible reasons for differences between studies. Only
the duration of follow-up correlated with the effects of
treatment on GFR. That the difference in change in GFR
of randomized controlled trials employing statistical tech- between treatment and control did not correlate with
niques similar to those used in the current study, the the difference in change in cholesterol probably reflects
difference between patients treated with converting en- that the degree of change in cholesterol did not differ
zyme inhibitors compared with controls was 1.6 (1.2 to significantly across studies. It should not be taken to
1.9) mL/min/year [30]. In contrast, the effect on change mean that the reduction in cholesterol was unimportant.
in GFR of low protein diet was only 0.53 (0.08 to 0.98) There was a possible trend for study duration to correlate
mL/min/year in a similar meta-analysis [31]. with changes in proteinuria. However, the statistical
We also examined the effects of lipid-lowering thera- power of this analysis may be too low to determine
pies on proteinuria. In this analysis, there appeared to whether the underlying disease process (for example,
be significant heterogeneity between the trial results diabetic nephropathy) or other variables influence the
(Fig. 4). Therefore, we attempted to combine these trials response to lipid-lowering therapy. Had we been able
using a random effects model. There appeared to be a to obtain individual patient data for more of the studies,
tendency for a reduction in protein excretion with lipid- we could have more fully examined the effect of other
lowering treatment; however, this result should be inter- variables [34].
preted with caution. With any meta-analysis, publication bias and “file-
drawer” bias may significantly influence the results. Pub-There are several important limitations to this meta-
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lication bias results when small trials showing weak or cations for therapy of patients with renal disease, because
negative effects are less often published [35]. We tried large, multicenter, randomized, controlled trials to deter-
to avoid this potential source of bias by including both mine definitively whether lipid-lowering agents slow the
published and unpublished (abstracts to meetings) trials. rate of renal disease progression may never be carried
However, it is possible that a number of trials that failed out. If a randomized trial was to be planned, we esti-
to show a beneficial effect of lipid-lowering therapy on mated that it would need to have 2600 subjects to have
renal function or proteinuria were never submitted for sufficient power (80%) to examine the impact of lipid
presentation at meetings and were never published, and reduction on progression of renal disease (assuming that
thus were subject to “file-drawer bias.” To screen for the difference in GFR was the same as the aggregate
both publication and “file-drawer bias,” we constructed value in our study and using the median variance across
funnel plots. These plots did not suggest that publication the studies that we found). However, there is growing
bias was present (Figs. 2 and 5). Had there been publica- evidence that cardiovascular disease is prevalent in pa-
tion bias, we may have expected to find fewer studies tients with renal disease and that hyperlipidemia may
appearing on the “negative result” side of the pooled play an important role in its pathogenesis [48]. There-
treatment effect line toward the left side of the graph, fore, it may be unethical to include an untreated control
suggesting the selective exclusion of smaller studies that group of hyperlipidemic patients with renal disease in a
reported negative results [26]. Of course, this and other clinical trial requiring long-term follow-up. Indeed, the
tests of publication bias do not exclude the possibility majority of patients with renal disease have hyperlipid-
that significant publication bias in fact exists. emia as well as other cardiovascular disease risk factors
The exact mechanism by which hyperlipidemia wors- that would make lipid-lowering therapy difficult to with-
ens renal disease is not known. Hyperlipidemia alone
hold in a placebo control group. Indeed, the American
does not appear to cause renal disease, although patients
Diabetes Association and the National Kidney Founda-with hereditary lipid disorder, such as lecithin-choles-
tion now recommend strict control of lipoprotein levelsterol acyltransferase deficiency, develop proteinuria and
for diabetics and those with chronic renal failure, respec-renal failure [36]. Biopsy of patients with this disorder
tively (greater than half of the studies in this meta-analy-reveal foam cells in the glomeruli with lipid deposition
sis were in diabetics) [48, 49]. These groups recommendin the glomerular basement membrane and mesangium.
starting pharmacological therapy for a LDL .130 mg/dLGlomerulosclerosis is correlated with the presence of
(3.37 mmol/L) and targeting LDL ,100 mg/dL (2.59atherosclerosis, leading investigators to suggest similar
mmol/L) for those without a history of cardiovascularpathologic mechanisms [37, 38]. Mesangial cells resemble
disease.vascular smooth muscle cells and respond to many of
In conclusion, the results of this meta-analysis suggestthe same stimuli [38]. In tissue culture assays, mesangial
that lipid-lowering therapy in patients with renal insuffi-cells express receptors for LDL cholesterol and LDL or
ciency may help slow the rate of renal disease progres-very LDL promotes mesangial cell proliferation [39, 40].
sion. It is clear that therapy with newer lipid-loweringLDL stimulates fibronectin and chemoattractant produc-
agents is relatively safe in patients with nephrotic syn-tion, which could lead to increased mesangial matrix and
drome and renal insufficiency [29]. It is also increasinglyrecruitment of inflammatory cells [41]. This response
apparent that hyperlipidemia may contribute to the car-could then worsen the renal disease and set up a vicious
diovascular disease that is so prevalent in this patientcircle in which the worsening renal disease then worsens
population. This meta-analysis lends further support tothe hyperlipidemia.
the argument that hyperlipidemia should be treated inReduction of lipid levels may also have hemodynamic
effects that could be relevant to the mechanism of im- patients with nephrotic syndrome and/or renal insuffi-
provement of GFR. Treatment with lipid-lowering medi- ciency.
cations has been shown to lower peripheral vascular re-
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